Cancer breakthroughs add pressure to control costs
(Reuters) - An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers and insurers will be under pressure to find savings elsewhere to pay for the high price tags of the new treatments. Doctors at this week's annual meeting of the American Society of Clinical Oncology heard groundbreaking data on a new class of immune system boosters that some believe will become the main treatment for more than half of all cancers in the next 10 years. They included drugs from Bristol-Myers Squibb and Merck & Co that shrank tumors in patients with advanced melanoma and lung cancer.
- Will More Pioneer ACOs Defect?
- Interventional Radiology No Longer a Sub-Specialty
- Charity HealthCare Conundrum Brewing Among Providers
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- mHealth Tackles Readmissions
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013